High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

Atkins et al. (Thu,) studied this question.

www.synapsesocial.com/papers/69dcd76b93ad366770e52ed4 — DOI: https://doi.org/10.1200/jco.1999.17.7.2105

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma IV. Late results after complete response to chemotherapy (central oncology group protocols 7130, 7131, and 7131A)· 1984 · 165 citations
2. Interferons in melanoma· 1996 · 81 citations
3. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.· 1995 · 142 citations
4. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial.